What happened
A recent study has revealed that a vaccine administered during pregnancy can reduce hospital admissions of babies for respiratory syncytial virus (RSV) by 80%. The vaccine, given to expectant mothers, boosts antibodies passed to the infant, providing strong protection against RSV — a common cause of severe respiratory illness in young children.
Why it matters
RSV is a leading cause of hospitalization in infants worldwide, with no widely effective treatment available. By preventing severe RSV infections through maternal vaccination, healthcare systems can significantly reduce the number of infant hospital stays, easing the burden on hospitals and improving infant health outcomes. This breakthrough also paves the way for broader adoption of maternal immunization strategies to protect newborns from infectious diseases.
Background
Respiratory syncytial virus primarily affects children under two years old, often causing bronchiolitis and pneumonia. While most cases are mild, RSV can be severe or even fatal in infants, especially those born prematurely or with underlying health issues. Currently, prevention strategies are limited, mostly relying on infection control measures. The development and testing of an RSV vaccine for pregnant women have been a significant focus in recent years, with the goal of protecting infants during their most vulnerable early months.
Questions and Answers
Q: How does the pregnancy RSV vaccine work?
A: The vaccine stimulates the mother’s immune system to produce antibodies, which are then transferred to the baby through the placenta, providing passive immunity against RSV in the first months of life.
Q: When during pregnancy is the vaccine administered?
A: The vaccine is typically given during the late second or early third trimester to maximize antibody transfer to the fetus.
Q: Is the vaccine safe for both mother and baby?
A: Clinical trials have shown the vaccine to be safe, with no significant adverse effects reported for either the mother or the infant.
Q: Will this vaccine be widely available soon?
A: Regulatory approval is underway, and experts anticipate the vaccine will become commercially available within the next few years, pending final review and manufacturing scale-up.
Source: https://www.bbc.com/news/articles/c4g84nxwz8wo?at_medium=RSS&at_campaign=rss